M1/M2 macrophage-targeted nanotechnology and PROTAC for the treatment of atherosclerosis

作者：Yupeng Ma, Xiaofan Yang, Ke Ning, Haidong Guo · 发表于：Life Sciences · 年份：2024 · DOI：10.1016/j.lfs.2024.122811 · 被引用次数：20 · 研究领域：Protein Degradation and Inhibitors、Ubiquitin and proteasome pathways、Peptidase Inhibition and Analysis

Macrophages play key roles in atherosclerosis progression, and an imbalance in M1/M2 macrophages leads to unstable plaques; therefore, M1/M2 macrophage polarization-targeted treatments may serve as a new approach in the treatment of atherosclerosis. At present, there is little research on M1/M2 macrophage polarization-targeted nanotechnology. Proteolysis-targeting chimera (PROTAC) technology, a targeted protein degradation technology, mediates the degradation of target proteins and has been widely promoted in preclinical and clinical applications as a novel therapeutic modality. This review summarizes the recent studies on M1/M2 macrophage polarization-targeted nanotechnology, focusing on the mechanism and advantages of PROTACs in M1/M2 macrophage polarization as a new approach for the treatment of atherosclerosis.